Direct renin inhibitors as antihypertensive agents

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Nephrology

Background:

• Hypertension affects 25% of adults globally, posing significant risks for cardiovascular and renal diseases.
• Despite available treatments, many hypertensive patients have uncontrolled blood pressure, leading to severe morbidity and mortality.
• Optimal hypertension management requires addressing all cardiovascular risk factors and preventing end-organ damage.

Purpose of the Study:

• To explore new therapeutic strategies for hypertension beyond current treatments.
• To investigate the role of renin inhibition in managing high blood pressure and related disorders.
• To evaluate the efficacy of novel renin inhibitors in controlling blood pressure.

Main Methods:

• Identification of renin inhibition as a key pharmacologic strategy to block the renin-angiotensin system.
• Utilizing molecular modeling to develop effective renin inhibitors, such as aliskiren.
• Assessing the sustained suppression of plasma renin activity and dose-dependent blood pressure reduction following oral administration.

Main Results:

• Development of clinically effective renin inhibitors, including aliskiren, through molecular modeling.
• Demonstrated sustained suppression of plasma renin activity after oral administration.
• Observed a dose-dependent reduction in blood pressure with new renin inhibitors.

Conclusions:

• Renin inhibition represents a significant advancement in antihypertensive pharmacotherapy.
• Aliskiren and similar agents show potential for improved blood pressure control in hypertensive patients.
• Further research is needed to establish the definitive role of renin inhibition in managing hypertension and cardiovascular diseases.